About Us

TREVENTIS™ Corporation is dedicated to treating and preventing protein misfolding diseases. Our innovative drug programs, powered by a combination of unique computational models and deep wetware expertise, aim to stop misfolding of proteins for potential disease modifying therapies in a variety of indications.  Our lead program is developing a differentiated collection of narrow and broad-spectrum anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimer’s disease. We have further efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.